{"type":"trials","record":{"id":41756,"source_id":"clinicaltrials-gov","external_id":"NCT03823300","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","brief_summary":"This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Hoffmann-La Roche","enrollment":658,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","China","Denmark","France","Germany","Hong Kong","Hungary","Italy","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)"],"start_date":"2019-03-11","completion_date":"2022-01-07","last_update_date":"2025-07-11","source_url":"https://clinicaltrials.gov/study/NCT03823300","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Arm B: Aflibercept","organization":"Hoffmann-La Roche","interventions":["Faricimab","Aflibercept","Sham Procedure"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — From Baseline through Week 48","Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 — From Baseline through Week 60","Change From Baseline in BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48,…","Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…","Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…","Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…","Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…","Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged…","Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 5…","Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or…","Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged…","Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Tim…","Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged…","Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Tim…","Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","source_has_results":true},"controlled_terms":["Wet Macular Degeneration","Faricimab","Aflibercept","Sham Procedure"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct03823300","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-03-11 to 2022-01-07","comparator":"Arm B: Aflibercept","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.866Z","intervention":["Faricimab","Aflibercept","Sham Procedure"],"participants":658,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · TRIPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48 — From Baseline through Week 48","Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 52, 56, and 60 — From Baseline through Week 60","Change From Baseline in BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48,…","Percentage of Participants Gaining Greater Than or Equal to (≥)15, ≥10, ≥5, or ≥0 Letters From the Baseline BCVA in the…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 52, 56, and…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…","Percentage of Participants Gaining ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8…","Percentage of Participants Gaining ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…","Percentage of Participants Gaining ≥0 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline, Weeks 4, 8,…","Percentage of Participants Avoiding a Loss of ≥15, ≥10, or ≥5 Letters From the Baseline BCVA in the Study Eye Averaged…","Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Averaged Over Weeks 5…","Percentage of Participants Avoiding a Loss of ≥15 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Avoiding a Loss of ≥10 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Avoiding a Loss of ≥5 Letters From the Baseline BCVA in the Study Eye Over Time — Baseline,…","Percentage of Participants Gaining ≥15 Letters From the Baseline BCVA or Achieving BCVA Snellen Equivalent of 20/20 or…","Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Averaged…","Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better (BCVA ≥69 Letters) in the Study Eye Over Tim…","Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Averaged…","Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse (BCVA ≤38 Letters) in the Study Eye Over Tim…","Percentage of Participants in the Faricimab Arm on Once Every 8-Weeks, 12-Weeks, or 16-Weeks Treatment Intervals Among…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41756","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}